CN105852118A - 抗反流婴儿营养物 - Google Patents
抗反流婴儿营养物 Download PDFInfo
- Publication number
- CN105852118A CN105852118A CN201610178267.9A CN201610178267A CN105852118A CN 105852118 A CN105852118 A CN 105852118A CN 201610178267 A CN201610178267 A CN 201610178267A CN 105852118 A CN105852118 A CN 105852118A
- Authority
- CN
- China
- Prior art keywords
- purposes
- alimentation composition
- weight
- gum
- lactalbumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000151 anti-reflux effect Effects 0.000 title description 12
- 235000021125 infant nutrition Nutrition 0.000 title description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims abstract description 36
- 239000005018 casein Substances 0.000 claims abstract description 34
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000021240 caseins Nutrition 0.000 claims abstract description 34
- 239000002562 thickening agent Substances 0.000 claims abstract description 25
- 229920000926 Galactomannan Polymers 0.000 claims abstract description 18
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 75
- 235000013336 milk Nutrition 0.000 claims description 56
- 239000008267 milk Substances 0.000 claims description 56
- 210000004080 milk Anatomy 0.000 claims description 56
- 229920000161 Locust bean gum Polymers 0.000 claims description 49
- 239000000711 locust bean gum Substances 0.000 claims description 49
- 235000010420 locust bean gum Nutrition 0.000 claims description 49
- 238000000855 fermentation Methods 0.000 claims description 41
- 230000004151 fermentation Effects 0.000 claims description 41
- 229920001542 oligosaccharide Polymers 0.000 claims description 37
- 102000004407 Lactalbumin Human genes 0.000 claims description 36
- 108090000942 Lactalbumin Proteins 0.000 claims description 36
- 150000002482 oligosaccharides Chemical class 0.000 claims description 28
- 238000006384 oligomerization reaction Methods 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 11
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 10
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 10
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims description 10
- 239000000213 tara gum Substances 0.000 claims description 9
- 235000010491 tara gum Nutrition 0.000 claims description 9
- 241000416162 Astragalus gummifer Species 0.000 claims description 8
- 229920001615 Tragacanth Polymers 0.000 claims description 8
- 235000014633 carbohydrates Nutrition 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 235000010487 tragacanth Nutrition 0.000 claims description 8
- 239000000196 tragacanth Substances 0.000 claims description 8
- 229940116362 tragacanth Drugs 0.000 claims description 8
- 229920002907 Guar gum Polymers 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- 239000000665 guar gum Substances 0.000 claims description 7
- 235000010417 guar gum Nutrition 0.000 claims description 7
- 229960002154 guar gum Drugs 0.000 claims description 7
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 230000035764 nutrition Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- 235000014103 egg white Nutrition 0.000 claims description 3
- 210000000969 egg white Anatomy 0.000 claims description 3
- -1 galactomannan Polysaccharide Chemical class 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 235000013350 formula milk Nutrition 0.000 abstract description 14
- 108010046377 Whey Proteins Proteins 0.000 abstract 1
- 102000007544 Whey Proteins Human genes 0.000 abstract 1
- 235000015140 cultured milk Nutrition 0.000 abstract 1
- 235000021119 whey protein Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 42
- 210000000481 breast Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 description 12
- 239000008101 lactose Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 7
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 210000003238 esophagus Anatomy 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 235000020256 human milk Nutrition 0.000 description 6
- 210000004251 human milk Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 description 4
- 240000008886 Ceratonia siliqua Species 0.000 description 4
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- AJNVQOSZGJRYEI-UHFFFAOYSA-N digallium;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Ga+3].[Ga+3] AJNVQOSZGJRYEI-UHFFFAOYSA-N 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 3
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- 244000303965 Cyamopsis psoralioides Species 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940077731 carbohydrate nutrients Drugs 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960002737 fructose Drugs 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 235000019580 granularity Nutrition 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 235000017367 Guainella Nutrition 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000013913 Ceratonia Nutrition 0.000 description 1
- 241001060815 Ceratonia Species 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000286862 Siliqua Species 0.000 description 1
- 229920000377 Sinistrin Polymers 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940043431 ceratonia Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/137—Thickening substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/25—Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pediatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于预防胃‑食管反流的婴儿配方乳,其包含乳清蛋白和/或酪蛋白、半乳甘露聚糖增稠剂和发酵乳衍生产物。
Description
本申请为分案申请,其原申请的申请日为2010年4月15日,申请号为201080025401.2(国际申请号PCT/NL2010/050192),名称为“抗反流婴儿营养物”。
技术领域
本发明属于抗反流营养物领域。本发明特别有利于婴儿。
背景技术
胃-食管反流(GER)是指胃内容物向上反流至食管,有时甚至进入或溢出口中。在食管的下端,下食管括约肌(LES)在吞咽食物时张开,然后在正常情况下关闭以使胃内容物保持在合适的位置。
当所述LES工作不正常时,GER使得包括盐酸的胃内容物接触食管、咽喉、鼻腔、肺和/或牙齿,造成疼痛和损伤。久而久之,这些区域与酸的反复接触可导致损伤增加并导致更严重的并发症。
至少50%的婴儿由于LES不成熟而伴随某种程度的GER出生。这些婴儿的大多数不会具有严重并发症并会在一岁前因长大而消除此症。据估计约3%的婴儿不会因长大而消除此症并会经历更严重的与胃-食管反流病(GERD)有关的并发症。
因此,GER(D)是一种尤其在婴儿期发生的问题。除了上述已经提到的问题以外,婴儿中的GER(D)还可导致婴儿脱水、生长受损和/或生长不良。
Nutrilon A.R.1是一种市售的针对患有GER的婴儿的婴儿配方乳。其每100ml包含0.4g增稠剂槐豆胶。其每100ml包含1.6克蛋白质,其中酪蛋白与乳清蛋白的重量比为8比2。
Gallia A.R.1是一种市售的婴儿配方乳,每100ml包含0.5g增稠剂槐豆胶。其针对患GER的婴儿。其包含1.6克蛋白质,其中酪蛋白与乳清蛋白的重量比为6比4。
EP 0 745 330公开了一种婴儿配方乳,其含有马铃薯淀粉、蜡质谷物淀粉(例如蜡质玉米淀粉、蜡质大米淀粉)或其混合物,作为可用于治疗回流的增稠剂。不利的是,淀粉取代乳糖作为可消化碳水化合物来源是不理想的,因为乳糖是人乳中可消化碳水化合物的主要来源。而且,淀粉可被α-淀粉酶降解,因此作为增稠剂效率较低。
EP 0 611 525公开了一种婴儿乳,其通过预加热、加入0.3-1%(以灭菌、包装的乳的总重计)的角豆、瓜尔豆、角叉菜和/或果胶作为增稠剂、均化、在超高温下处理和包装制备。
FR 2913857公开了粉末形式的抗回流婴儿乳的制备和包含以干重计1-5重量%角豆粉的婴儿乳粉。
JP2003245039公开了一种适用于婴儿胃-食管反流病的饮食治疗的胃-食管反流抑制配方乳,其粘度在溶解时较低而在吸取后增加。
EP 1 930 407A1公开了具有杀死幽门螺旋杆菌(Helicobacterpylori)作用、并且即使是保存在有氧条件下的发酵乳品和饮料中时也显示出高存活率的双岐双岐杆菌(Bifidobacterium bifidum)。
发明内容
本发明人意外地发现包含发酵乳衍生产物(特别是用嗜热乳酸链球菌(Streptococcus thermophilus)发酵的乳)和半乳甘露聚糖增稠剂(特别是槐豆胶)的婴儿配方乳(IMF)会产生更稠、特别是在胃中更稠的产物。
本发现的有益效果是所述婴儿营养产品中LBG的量相对常规组合物减少,同时保持现有技术中IMF的有利的抗反流特性。
这提供了一些优点,主要是因为i)LBG昂贵,ii)LBG的存在使得存在细菌感染的危险,因为半乳甘露聚糖源经常被细菌污染,并且难以不使所述产品降解而灭菌,以及iii)减少LBG的量使得可加入其他纤维,特别是非消化性寡糖(NDO)。通常不向含有LBG的婴儿配方乳中加入NDO以使纤维量保持在某一上限之下。尤其是过多的纤维量可导致腹部不适,例如胃气胀和痉挛。在LBG含量减少的情况下,可加入益生纤维(prebotics)例如NDO,与LBG相比,所述益生纤维选择性地对例如益菌保护性(bifidogenicity)有更好的作用。在含LBG的配方乳中共同给予例如反式寡聚半乳糖(TOS)和/或寡聚果糖(FOS)会进一步减轻腹部痉挛、疼痛、胃气胀等,这对患有GER或有GER危险的婴儿特别有益。
减少LBG的量的另一优点是iv)可降低酪蛋白的量和/或酪蛋白与乳清蛋白的比例。目前,酪蛋白通常以1或更高的相对高比例存在于抗反流配方乳中。酪蛋白的摄入导致在胃中形成对防止GER有益的粗凝乳。本发现使得乳清蛋白与酪蛋白的比例更接近在人乳中观察到的比例(6比4)。这导致更接近人乳的改善的氨基酸谱,并因此导致可降低至更接近人乳中水平的蛋白质含量,而不损害生长。另一结果可为以总能量计的蛋白质量可降低。以此方式,所述蛋白质浓度会有利地更接近于人乳中的蛋白质浓度。
具体实施方式
本发明因此涉及一种预防胃-食管反流的方法,和/或一种预防和/或治疗胃-肠反流病的方法,所述方法包括给予一种包含以下组分的营养组合物:a)乳清蛋白和/或酪蛋白,b)选自以下的增稠剂:槐豆胶、他拉胶、黄蓍胶、瓜尔豆胶和香豆胶(fenugreek gum),以及c)发酵乳衍生产物。
换言之,本发明涉及增稠剂用于制备一种用于预防胃-食管反流、并且/或者用于预防和/或治疗胃-肠反流病的营养组合物的用途,其中所述营养组合物包含:a)乳清蛋白和/或酪蛋白,b)选自以下的所述增稠剂:槐豆胶、他拉胶、黄蓍胶、瓜尔豆胶和香豆胶,以及c)发酵乳衍生产物。
本发明还可表述为一种用于预防胃-食管反流、并且/或者用于预防和/或治疗胃-肠反流病的营养组合物,所述组合物包含以下组分:a)乳清蛋白和/或酪蛋白,b)选自以下的增稠剂:槐豆胶、他拉胶、黄蓍胶、瓜尔豆胶和香豆胶,以及c)发酵乳衍生产物。
本发明的另一方面提供一种包含以下组分的营养组合物:a)乳清蛋白和/或酪蛋白,b)选自以下的增稠剂:槐豆胶、他拉胶、黄蓍胶、瓜尔豆胶和香豆胶,以及c)发酵乳衍生产物。
在一个优选实施方案中,本发明用于为婴儿提供营养或者本发明组合物用于为婴儿提供营养。
胃食管反流
胃食管反流(GER)是指胃内容物向上反流至食管。在婴儿中,GER可包括反流物质仅进入食管远端(底部)以及呕吐甚至经常的喷射性呕吐。回流、胃灼热或酸反流也是GER形式。胃肠反流病(GERD)是一种出现严重并发症的胃-肠反流形式。GERD是一种病理过程并且所述并发症可为典型的,例如发育停滞、厌食、食管炎等,也可为非典型的,例如喘鸣、肺炎、慢性窦炎等。GERD的患者具有必须进行医疗介入的起源于GER的并发症。GERD也称为“病理性GER”。
发酵乳衍生产物
本发明的组合物包含发酵乳衍生产物。该发酵乳衍生产物是通过孵育乳(例如脱脂乳)或者乳衍生产物(例如乳糖)与至少一种微生物(优选嗜热链球菌)的结合物而获得的。优选地,将所述结合物孵育10分钟至约6小时。孵育过程中的温度优选为20至50℃。孵育后,优选将所述孵育产物进行热处理。通过该热处理,优选至少90%的活微生物被灭活。所述热处理优选在80-180℃之间的温度下进行。适合本发明目的的制备发酵乳衍生产物的方法本身是已知的。EP778885,其以引用的方式纳入本文,具体在实施例7中公开了一种用于制备发酵乳衍生产物的合适方法。FR 2723960,其以引用的方式纳入本文,具体在实施例6中公开了一种用于制备发酵乳衍生产物的合适方法。
简言之,将含有乳糖并任选地含有其他主要营养素例如(植物)脂肪、酪蛋白、乳清蛋白、维生素和/或矿物质等、优选经过巴氏灭菌的乳衍生产物浓缩至例如15-50%干物质,然后接种以嗜热链球菌,例如以每毫升含有106-1010个细菌的5%培养物。发酵温度和持续时间如上述。合适地,可在发酵后将所述发酵乳衍生产物进行巴氏灭菌或消毒,以及例如喷雾干燥或冻干,以提供一种适于被配制在还含有半乳甘露聚糖增稠剂的终产物中的形式。
优选用于为了本发明目的制备所述发酵乳衍生产物的嗜热链球菌的菌株在所述底物的发酵过程中产生β-半乳糖苷酶活性。优选地β-半乳糖苷酶活性与酸度同时产生。优选地,产生的β-半乳糖苷酶活性足以允许随后发酵乳衍生产物的寡聚半乳糖富集。因此,优选地,合适的嗜热链球菌菌株,当培养在含有乳糖的培养基(特别是基于乳浓缩物的培养基)上时,伴随着寡聚半乳糖的大量生产实现所述培养基的发酵。EP 778885的实施例2和FR 2723960的实施例1中描述了嗜热链球菌的合适菌株的选择。然后选择优选的嗜热链球菌菌株,其产生β-半乳糖苷酶活性也产生寡聚半乳糖。
制备本发明的发酵乳衍生产物的优选嗜热链球菌菌株由Compagnie Gervais Danone于1995年8月23日(保藏号为I-1620)和1994年8月25日(保藏号为I-1470)保藏在Institut Pasteur,25ruedu Docteur Roux,Paris,France的Collection Nationale de Culturesde Microorganismes(CNCM)。
优选地,在发酵乳衍生产物的制备中,还同时或相继存在其他乳酸细菌菌株,所述发酵乳衍生产物还被其他乳酸细菌菌株发酵。其他乳酸细菌菌株优选地选自乳酸杆菌(Lactobacillus)和双歧杆菌(Bifidobacteria),更优选短双歧杆菌(Bifidobacterium breve),最优选由Compagnie Gervais Danone于1999年5月31日以保藏号I-2219保藏在CNCM的短双歧杆菌菌株。
本发明组合物优选包含以总产品的干重计5-100重量%的发酵乳衍生产物。在一个实施方案中,本发明组合物优选包含以总产品的干重计5-70重量%、优选10-40重量%的发酵乳衍生产物。在一个实施方案中,本发明组合物优选包含以总产品的干重计20-100重量%、优选50-100重量%、甚至更优选50-95%的发酵乳衍生产物。发酵产品的更高浓度有利地提高了在胃中的粘度。
半乳甘露聚糖
本发明组合物每100g总产品干重优选地包含小于4g、优选小于3g、优选约0.3到小于3g、优选小于2.5g的半乳甘露聚糖增稠剂,更优选每100g总产品干重包含0.3到2g、更优选0.3到1.5g半乳甘露聚糖增稠剂。本发明组合物每100ml液体产品优选包含小于0.5g、优选小于0.3g、优选约0.04到小于0.3g半乳甘露聚糖增稠剂。在一个优选实施方案中,所述半乳甘露聚糖增稠剂为槐豆胶(LBG)。
槐豆胶(LBG),也称为角豆胶,是豆科的角豆树(Ceratoniasiliqua)的产物。所述角豆树产生长豆荚,其在去掉外皮和中胚层(central germ)后暴露出胚乳层。通常该胚乳是所需胶的来源。已知槐豆胶为半乳甘露聚糖。通常将半乳甘露聚糖定义为由甘露糖骨架与半乳糖侧基构成的多糖。更具体地,本发明的LBG可被描述为(1-4)-交联的β-D-甘露聚糖骨架,其中第6位上的分支点连接于α-D-半乳糖,即1-6-交联的α-D-半乳糖侧基。
多个级别的LBG是可用的,对于每一级别,根据最终用户的要求可以具有不同的粒度。在本发明的上下文中,优选使用LBG粉末,其中小于20重量%的LBG颗粒具有大于200微米的粒度,优选小于10重量%的LBG颗粒具有大于200微米的粒度。
非消化性寡糖
本发明组合物优选包含非消化性寡糖,所述非消化性寡糖不同于蔗糖、乳糖、麦芽糖以及未进一步详细说明的麦芽糊精,其被认为可消化性的。非消化性寡糖优选地促进肠道乳酸产生细菌特别是双歧杆菌和/或乳酸杆菌的生长。优选地,所述非消化性寡糖是中性寡糖。本发明使用的术语“中性寡糖”是指其中多于75%、优选多于85%、更优选多于95%、甚至更优选多于99%的糖单元为选自葡萄糖、果糖、半乳糖、甘露糖、核糖、鼠李糖、阿拉伯糖和木糖的寡糖。优选地,本发明的非消化性寡糖是可溶的。当本文所用的术语“可溶的”涉及多糖、纤维或寡糖时,是指所述物质根据L.Prosky et al.,J.Assoc.Off.Anal.Chem.71,1017-1023(1988)所述的方法是至少可溶的。
优选地,本发明组合物包含至少一种选自以下的非消化性寡糖:寡聚半乳糖(galacto-oligosaccharide)、非消化性糊精、寡聚木糖(xylo-oligosaccharide)、寡聚阿拉伯糖(arabino-oligosaccharide)、寡聚葡萄糖(gluco-oligosaccharide)(例如寡聚龙胆糖(gentio-oligosaccharide)和环糊精)、壳寡聚糖(chito-oligosaccharide)、寡聚岩藻糖(fuco-oligosaccharide)、寡聚甘露糖(manno-oligosaccharide)、寡聚异麦芽糖(isomalto-oligosaccharide)、寡聚果糖(fructo-oligosaccharide)(例如菊粉)、寡聚半乳甘露糖(galactomanno-oligosaccharide)、寡聚葡甘露糖(glucomanno-oligosaccharide)、寡聚阿拉伯半乳糖(arabinogalacto-oligosaccharide)。
作为发酵过程的结果,依照本发明纳入的所述发酵乳衍生产物可以已经含有寡聚半乳糖。因此,在一个实施方案中,本发明组合物包含至少一种寡聚半乳糖以外的非消化性寡糖。优选地,本发明组合物至少包含寡聚果糖。本文所用的术语“寡聚果糖”是指包含至少2个β-交联的果糖单元的链、且DP为2-250、优选7-100、更优选20-60的非消化性多糖碳水化合物。优选使用菊粉。菊粉以商品名“Raftilin”(Orafti)市售。本发明寡聚果糖的平均DP优选地为至少7、更优选至少10、优选小于100。寡聚果糖的其他术语包括菊粉、低聚果糖(fructopolysaccharide)、多聚果糖、果聚糖和果寡糖(oligofructose)。本发明组合物优选包含DP为2至100的寡聚果糖。
在一个实施方案中,本发明组合物包含以总组合物的干重计3-9重量%、更优选3-6重量%的非消化性寡糖。
本发明组合物优选地包含至少两种具有不同平均聚合度(DP)的非消化性(中性)寡糖。优选地,其重量比为:
a.(DP为2-5的非消化性(中性)寡糖):(DP为6、7、8和/或9的非消化性(中性)寡糖)>1;和/或
b.(DP为10-60的非消化性(中性)寡糖):(DP为6、7、8和/或9的非消化性(中性)寡糖)>1。
优选地,所述两个重量比均大于2,更优选大于5。
为进一步改进,本发明非消化性寡糖优选含有较高含量的短链寡糖,因为这些短链寡糖强烈刺激双歧杆菌的生长。因此,在本发明组合物中优选至少10重量%的非消化性寡糖具有2-5(即2、3、4和/或5)的DP并且至少5重量%的非消化性寡糖具有10-60的DP。更优选地,至少50重量%、更优选至少75%的非消化性中性寡糖具有2-9(即2、3、4、5、6、7、8和/或9)的DP。
如已经提到的,本发明组合物还可含有由所述乳衍生产物的发酵过程特别是由嗜热链球菌而产生的寡聚半乳糖。通常,用嗜热链球菌发酵获得的寡聚半乳糖是包含β-1,3-交联的糖单元的寡聚半乳糖。因此,在一个实施方案中,本发明组合物含有β-1,3-交联的寡聚半乳糖。
粘度
本发明组合物的粘度是在37℃的温度和10s-1的剪切速率下在带有MCR流变仪(modular compact rheometer)(Physica,MCR 300,AntonPaar Benelux)的同心圆筒中使用淀粉-桨-几何学(starch-paddle-geometry)测定的。即饮的营养组合物的粘度在约中性的pH例如约7±0.5的pH下进行了测定。所述粘度还在近似婴儿胃中的条件下,具体而言在约5的pH下,进行了测定。为此将13g粉末状的营养组合物溶解于90g水中。一部分不改变pH;将另一部分的pH降低至5.0。将全部样品均置于37℃下1小时。
在一个实施方案中,在中性pH下的本发明营养组合物在37℃的温度和10s-1的剪切速率下具有高于30mPa.s并优选低于80mPa.s的粘度。
在一个实施方案中,在pH 5.0下的本发明营养组合物具有高于80mPa.s、优选高于100mPa.s的粘度。优选地,在pH 5.0下的本发明营养组合物具有低于300mPa.s、更优选低于250mPa.s的粘度。
乳清蛋白和酪蛋白
本发明组合物包含乳清蛋白和/或酪蛋白。优选地,本发明组合物包含乳清蛋白和酪蛋白。本发明组合物中的乳清蛋白和/或酪蛋白包括存在于所述发酵乳衍生产物中的乳清蛋白和/或酪蛋白。在一个实施方案中,所述乳清蛋白和/或酪蛋白是部分水解的。
由于本发明组合物的有利的增稠性质,凝结酪蛋白在胃中的增稠效应不再是必需的。因此,与常规抗反流配方乳相比,可减少本发明组合物中酪蛋白的量。
有利地,酪蛋白的量的减少可导致本发明营养组合物的蛋白含量的总体减少,使其更近似于人乳中的蛋白含量。因此,在一个实施方案中,本发明组合物每100ml液体产品包含少于1.6g、优选少于1.5g的蛋白质。在本发明组合物的一个实施方案中,酪蛋白和乳清蛋白的总和以总组合物的干重计小于15重量%,更优选小于10重量%。
因此,在一个实施方案中,本发明涉及一种包含以下组分的营养组合物:a)乳清蛋白和/或酪蛋白,其中酪蛋白和乳清蛋白的总和以总组合物的干重计小于15重量%,b)选自以下的增稠剂:槐豆胶、他拉胶、黄蓍胶、瓜尔豆胶和香豆胶,以及c)以总产品干重计5-100重量%的发酵乳衍生产物。
或者,酪蛋白的量的减少使得可使用更多量的乳清蛋白,这是有利的,因为乳清蛋白的营养价值高。因此,在本发明组合物的一个实施方案中,酪蛋白与乳清蛋白的重量比为1或更低,优选小于1。在一个优选实施方案中,酪蛋白与乳清蛋白的重量比为约0.67,其与人乳中的该比例相当。
其他主要营养素
本发明组合物优选包含对于抗反流或抗回流配方乳而言为常规量的脂肪。优选地,本发明组合物包含植物脂肪。优选地,本发明组合物包含亚油酸(LA;18:2n6)和α-亚麻酸(ALA;18:3n3)。
本发明组合物优选包含对于抗反流或抗回流配方乳而言为常规量的可消化的碳水化合物。优选地,本发明组合物包含可消化的碳水化合物。优选地,本发明组合物包含乳糖。
在一个方面中,本发明涉及一种包含蛋白、脂质和碳水化合物并包含以下组分的营养组合物:a)乳清蛋白和/或酪蛋白,其中乳清蛋白和酪蛋白的总和以总组合物的干重计小于15重量%,b)选自以下的增稠剂:槐豆胶、他拉胶、黄蓍胶、瓜尔豆胶和香豆胶,以及c)以总产品干重计20-100重量%的发酵乳衍生产物。上面提到的所有优选实施方案,特别是在所述发酵乳衍生产物、半乳甘露聚糖、非消化性寡糖、粘度、乳清蛋白和酪蛋白的来源和性质以及在其他主要营养素的性质方面,也适用于本发明的这一方面。
应用
本发明组合物优选用于预防胃-食管反流并且/或者用于预防和/或治疗胃-肠反流病。胃-食管反流(GER)是指胃内容物向上反流至食管,有时甚至进入或溢出口中。在食管的下端,下食管括约肌(LES)在吞咽食物时张开,然后在正常情况下关闭以使胃内容物保持在合适的位置。
本发明组合物优选给予0-12月龄、更优选0-6月龄的婴儿。优选地,本发明组合物给予LES尚未成熟的婴儿。
实施例:
实施例1发酵乳衍生产物的制备
将植物脂肪加入在75℃下加热的牛乳中。将此混合物分两步均质化,第一步在200kg.s/cm2下,第二步在50kg.s/cm2下。加入乳糖和麦芽糊精和维生素以及矿物质的水溶液。将所述组合物在115℃下进行巴氏灭菌并通过蒸发浓缩至48%干物质。将此浓缩物冷却至37℃,用含有108个细菌/ml的5%的嗜热链球菌I-1470的培养物接种并在44℃下孵育5.5小时。然后对所述发酵乳衍生产物进行喷雾干燥。
实施例2
针对0-6月龄婴儿的包装好的婴儿配方乳,每100ml包含:70kcal;3.1g脂肪(植物脂肪);1.4g蛋白质(0.6g乳清蛋白、0.8g酪蛋白);9.1g可消化性碳水化合物(乳糖大于50%);0.4g槐豆胶;15重量%的通过实施例1所述方法获得的发酵产物;以本领域所知的量存在的矿物质、微量元素、维生素、肉碱、牛磺酸、肌醇和胆碱。
所述包装带有“抗回流”的标签。
实施例3
针对0-6月龄婴儿的婴儿配方乳,每100ml包含:70kcal;3.1g脂肪(植物脂肪);1.4g蛋白(0.6g乳清蛋白、0.8g酪蛋白);9.1g可消化性碳水化合物(乳糖大于50%);0.25g槐豆胶;15重量%的通过实施例1所述方法获得的发酵产物;以本领域所知的量存在的矿物质、微量元素、维生素、肉碱、牛磺酸、肌醇和胆碱。
实施例4
针对0-6月龄婴儿的婴儿配方乳,每100ml包含:70kcal;3.1g脂肪(植物脂肪);1.4g蛋白质(0.6g乳清蛋白、0.8g酪蛋白);9.1g可消化性碳水化合物(乳糖大于50%);0.4g槐豆胶;50重量%的通过实施例1所述方法获得的发酵产物;以本领域所知的量存在的矿物质、微量元素、维生素、肉碱、牛磺酸、肌醇和胆碱。
实施例5:发酵产物和槐豆胶的结合物对粘度的影响
测试了发酵产物的存在与否对槐豆胶的粘度增加效应的影响。将槐豆胶(Meyprodin 200,Danisco)以不同浓度加入标准婴儿配方乳(Gallia 1,pH 6.8)或市售的包含发酵产物的婴儿配方乳(Lactofidus,pH 5.7)中。用Thermo Haake VT 5550设备在37℃和100s-1下测量粘度。表1中显示,在相同浓度的LBG下,含有发酵产物的婴儿配方乳的粘度高于不含发酵产物的标准IMF的粘度。
表1:在标准IMF或包含发酵产物的IMF中倚赖槐豆胶浓度的粘度增加。
在表2中示出了在保持槐豆胶的量(3重量%)恒定时,IMF中发酵产物的浓度对粘度的影响。通过以不同重量比混合非发酵IMF(Gallia 1)与发酵IMF(Lactofidus)来改变发酵产物的量。粘度的测量如上。结果显示,在LBG的值恒定时,发酵产物的量增加会导致粘度增加。
表2:含有LBG的IMF中发酵产物的浓度对粘度的影响。
这些结果表明发酵产物和半乳甘露聚糖增稠剂对粘度有增加效应。
实施例6:瓶中的IMF的粘度测量
进行实验来评估IMF在瓶中的的粘度的时间过程。用Anton Paar(Courtaboeuf,France)的MCR 300流变仪在10s-1和37℃下测量粘度,参数为geometry plan-plan 50,gap 2mm。在复原后0、15、30、45和60分钟采样。测试的IMF为:
1.本发明的抗反流配方乳,以不含LBG的组合物的干重计,包含15%的发酵IMF(Lactofidus)和85重量%的非发酵产品(Gallia 2),每100ml包含0.42g LBG,并且每100ml包含1.4g蛋白质,同时酪蛋白与乳清蛋白的重量比为6/4。
2.现有技术的抗反流配方乳(Gallia AR 2),不包含发酵产物,每100ml包含0.47g LBG,并且每100ml包含1.74g蛋白质,同时酪蛋白与乳清蛋白的重量比为6/4。
3.现有技术的抗反流配方乳(Enfamil AR 2),不包含发酵产物,每100ml包含2.2g米淀粉作为增稠剂,并且每100ml包含1.7g蛋白质,同时酪蛋白与乳清蛋白的重量比为8/2。
结果示于表3。由于LBG、蛋白质以及酪蛋白与乳清蛋白的比例不相似,因此只示出了相对变化,并将具体配方乳在时间=0时的值设定为1。从表3可推出,与原有的含有LBG而不含发酵产物的AR配方乳相比,在瓶中产生的粘度较低。这是有利的,因为在瓶中的低粘度使得更容易饮用和通过奶头上的小孔。不含LBG的产品(Gallia2和Lactofidus)的粘度<2mPa.s。
表3:瓶中的粘度变化
a:在t=0时粘度为35.6、48.8和47.1mPa.s
实施例7:在胃条件下的IMF的粘度测量
进行实验来评估IMF在婴儿的胃中的粘度的时间过程。在复原后0、15、30、45、75和90分钟如实施例6所述测量粘度。
在模仿4-12月龄婴儿的胃中条件的条件下测量各种IMF的粘度。大体上,向37℃下的210ml IMF加入20ml唾液(每升包含600mgα-淀粉酶、6.2g NaCl、2.2g KCl、0.22g CaCl2、1.2g NaHCO3,pH6.3),在5分钟后在90分钟内以75ml的量连续加入胃液(每升包含100mg胃蛋白酶、140mg脂肪酶、3.1g NaCl、1.1g KCl、0.11gCaCl2,pH 5.0)。pH通过加入HCl或NaHCO3进行调节。设置pH,使其在t=90时值下降至3.5。所测试的IMF在实施例6中有述。
结果示于表4。由于LBG、蛋白质以及酪蛋白与乳清蛋白的比例不相似,因此只示出了相对变化,并将具体配方乳在时间=0时的值设定为100%。从表4可推出,与原有的含有LBG而不含发酵产物的AR配方乳相比,并且与包含淀粉的AR配方乳相比,粘度增加并且在前75分钟、特别是在前60分钟内、更特别是在前30分钟内保持较高。这是有利的,因为在胃中较高粘度保持更长时间对预防胃-食管反流有积极作用。特别是60分钟内,更特别是前30分钟内是最重要的,因为大部分反流发生在此时间内。
表4:在胃条件下的粘度
a:在t=0时粘度为69.2、139和71.9mPa.s
Claims (16)
1.一种增稠剂用于制备用于预防胃-食管反流并且/或者用于预防和/或治疗胃-肠反流病的营养组合物的用途,其中所述营养组合物包含:
a)乳清蛋白和/或酪蛋白;
b)选自槐豆胶、他拉胶、黄蓍胶、瓜尔豆胶和香豆胶的增稠剂;和
c)发酵乳衍生产物。
2.权利要求1的用途,其中所述营养组合物用于为婴儿提供营养。
3.权利要求1或2的用途,其中所述营养组合物包含以总产品的干重计5-100重量%的发酵乳衍生产物。
4.前述权利要求任一项的用途,其中乳清蛋白和酪蛋白的总和以总组合物的干重计少于15重量%。
5.一种营养组合物,包含
a)乳清蛋白和/或酪蛋白;其中乳清蛋白和酪蛋白的总和以总组合物的干重计少于15重量%;
b)每100ml液体产品包含少于1.6g蛋白质;
c)选自槐豆胶、他拉胶、黄蓍胶、瓜尔豆胶和香豆胶的增稠剂;和
d)以总产品的干重计5-100重量%的发酵乳衍生产物。
6.一种包含蛋白质、脂质和碳水化合物并包含以下组分的营养组合物:
a)乳清蛋白和/或酪蛋白;其中乳清蛋白和酪蛋白的总和以总组合物的干重计少于15重量%;
b)选自槐豆胶、他拉胶、黄蓍胶、瓜尔豆胶和香豆胶的增稠剂;和
c)以总产品的干重计20-100重量%的发酵乳衍生产物。
7.前述权利要求任一项的用途或营养组合物,其中所述组合物是在约5.0的pH和37℃以及10s-1的剪切速率下具有80mPa.s或更高粘度的液体组合物。
8.前述权利要求任一项的用途或营养组合物,其中所述组合物是在中性pH和37℃以及10s-1的剪切速率下具有30-80mPa.s粘度的液体组合物。
9.前述权利要求任一项的用途或营养组合物,其中酪蛋白与乳清蛋白的重量比小于1。
10.前述权利要求任一项的用途或营养组合物,其中所述半乳甘露聚糖增稠剂是槐豆胶。
11.前述权利要求任一项的用途或营养组合物,所述组合物每100g干重包含小于2.5g半乳甘露聚糖增稠剂并且/或者每100ml包含小于0.5g半乳甘露聚糖增稠剂。
12.前述权利要求任一项的用途或营养组合物,还包含非消化性寡糖。
13.权利要求12的用途或营养组合物,包含至少一种、优选至少两种选自以下的非消化性寡糖:寡聚半乳糖、非消化性糊精、寡聚木糖、寡聚阿拉伯糖、寡聚葡萄糖、壳寡聚糖、寡聚岩藻糖、寡聚甘露糖、寡聚异麦芽糖、寡聚果糖、寡聚半乳甘露糖、寡聚葡甘露糖和寡聚阿拉伯半乳糖。
14.权利要求12或13的用途或营养组合物,所述组合物每100克总组合物干重包含3-9克非消化性寡糖。
15.前述权利要求任一项的用途或营养组合物,其中所述发酵乳衍生产物是用CNCM登记号为I-1470或I-1620的嗜热链球菌(Streptococcus thermophilus)菌株进行发酵的产物。
16.权利要求1-5和7-15任一项的用途或营养组合物,包含以总产品干重计5-70重量%的发酵乳衍生产物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09157995.3 | 2009-04-15 | ||
EP09157995 | 2009-04-15 | ||
CN2010800254012A CN102802439A (zh) | 2009-04-15 | 2010-04-15 | 抗反流婴儿营养物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800254012A Division CN102802439A (zh) | 2009-04-15 | 2010-04-15 | 抗反流婴儿营养物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105852118A true CN105852118A (zh) | 2016-08-17 |
Family
ID=42122823
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800254012A Pending CN102802439A (zh) | 2009-04-15 | 2010-04-15 | 抗反流婴儿营养物 |
CN201610178267.9A Pending CN105852118A (zh) | 2009-04-15 | 2010-04-15 | 抗反流婴儿营养物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800254012A Pending CN102802439A (zh) | 2009-04-15 | 2010-04-15 | 抗反流婴儿营养物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10602752B2 (zh) |
EP (1) | EP2418969B1 (zh) |
CN (2) | CN102802439A (zh) |
ES (1) | ES2410376T3 (zh) |
PL (1) | PL2418969T3 (zh) |
PT (1) | PT2418969E (zh) |
RU (1) | RU2524201C2 (zh) |
WO (1) | WO2010120172A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1841332T4 (da) | 2004-11-18 | 2013-05-06 | Nutricia Nv | Fortykningsmiddelsammensætning til dysfagipatienter |
EP2418969B1 (en) | 2009-04-15 | 2013-03-06 | N.V. Nutricia | Anti-reflux infant nutrition |
CN103974706A (zh) * | 2011-10-06 | 2014-08-06 | N·V·努特里奇亚 | 嗜酸细胞性食管炎的治疗 |
WO2013101494A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Two-phase mixable nutritional composition including locust bean gum |
WO2013187755A1 (en) * | 2012-06-14 | 2013-12-19 | N.V. Nutricia | Fermented infant formula with non digestible oligosaccharides |
FR3005392B1 (fr) * | 2013-05-07 | 2015-09-18 | United Pharmaceuticals | Composition anti-regurgitation preservant le transit intestinal |
US20230068996A1 (en) * | 2020-01-28 | 2023-03-02 | N.V. Nutricia | Formula with galactomannan gum and non digestible oligosaccharides |
CN117279522A (zh) * | 2021-05-31 | 2023-12-22 | 营养株式会社 | 营养组合物 |
CN113519625A (zh) * | 2021-07-12 | 2021-10-22 | 燎原乳业股份有限公司 | 一种防呕吐婴幼儿牦牛配方奶粉 |
WO2023003569A1 (en) * | 2021-07-23 | 2023-01-26 | Advanced Bionutrition Corp. | Dry and shelf-stable fermented milk product |
WO2024089060A1 (en) | 2022-10-25 | 2024-05-02 | N.V. Nutricia | Antiregurgitation formula |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1159207A (zh) * | 1994-08-31 | 1997-09-10 | 热尔韦·达诺尼公司 | 用嗜热链球菌制备富含半乳糖-低聚糖和β-半乳糖苷酶的发酵产品 |
CN101228262A (zh) * | 2005-07-21 | 2008-07-23 | 株式会社益力多本社 | 新型双歧杆菌属细菌及其利用 |
JP2008237186A (ja) * | 2007-03-29 | 2008-10-09 | Nof Corp | ゲル状流動食 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3721571A (en) | 1971-01-14 | 1973-03-20 | Gen Foods Corp | Pudding compositions |
US4105461A (en) | 1976-08-26 | 1978-08-08 | Merck & Co., Inc. | Thickening compositions containing xanthan gum, guar gum and starch |
US4542035A (en) | 1984-03-16 | 1985-09-17 | The Pillsbury Company | Stable aerated frozen dessert with multivalent cation electrolyte |
US4956185A (en) * | 1989-04-26 | 1990-09-11 | Milpak Inc. | Instant yogurt composition and process |
FR2699370B1 (fr) | 1992-12-17 | 1995-01-13 | Cedilac Sa | Procédé pour la fabrication d'un lait infantile liquide prêt à l'emploi longue conservation et anti-régurgitation, et lait ainsi obtenu. |
JP2838353B2 (ja) | 1993-12-28 | 1998-12-16 | ハウス食品株式会社 | デザート食品 |
FR2723960B1 (fr) | 1994-08-31 | 1996-10-11 | Gervais Danone Co | Cultures de streptococcus thermophilus a activite beta-galactosidase elevee, leur procede d'obtention, et leurs utilisations |
US5597603A (en) | 1995-02-28 | 1997-01-28 | Kraft Foods, Inc. | Sugar-free, fat-free instant pudding mix |
US6099871A (en) | 1995-06-01 | 2000-08-08 | Bristol-Myers Squibb Company | Anti-regurgitation infant formula |
US6277395B1 (en) | 1998-07-31 | 2001-08-21 | Ryukakusan Co. Ltd. | Swallowing-assistive drink |
ID25929A (id) | 1998-01-08 | 2000-11-09 | Otsuka Food Co Ltd | Produk makanan gelatin dan proses penyediaannya |
JP4248653B2 (ja) | 1998-12-28 | 2009-04-02 | ライオン株式会社 | 易嚥下補助組成物並びにこれを用いた食品用組成物及び医薬品用組成物 |
MXPA01013333A (es) | 1999-07-06 | 2002-07-09 | Nestle Sa | Composicion nutricional gelificada y proceso. |
US6461589B2 (en) | 1999-08-27 | 2002-10-08 | Wisconsin Alumni Research Foundation | Standardized compositions which facilitate swallowing in dysphagic subjects |
GB0015417D0 (en) | 2000-06-24 | 2000-08-16 | Cerestar Holding Bv | Agglomerated starch-based product for food preparation |
US20020044988A1 (en) | 2000-08-22 | 2002-04-18 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
US20030072729A1 (en) | 2001-05-15 | 2003-04-17 | Christopher Szymczak | Simethicone as weight gain enhancer |
EP2260722A3 (en) | 2001-08-02 | 2017-04-05 | Simply Thick LLC | Process for Preparing Concentrate Thickener Compositions |
JP3747028B2 (ja) * | 2001-12-20 | 2006-02-22 | 森永乳業株式会社 | 調製粉乳、胃食道逆流抑制調製粉乳、及び調製粉乳の製造方法 |
CA2467625C (en) | 2001-12-21 | 2011-04-12 | Sa Majeste La Reine Du Chef Du Canada | Method of preparation of adapted foods |
KR200290193Y1 (ko) | 2002-04-08 | 2002-09-26 | 김학성 | 레인지 후드 세척기 |
EP1380990A1 (en) | 2002-07-09 | 2004-01-14 | SCHLUMBERGER Systèmes | Data carrier being removably mounted on other data carrier of different type |
KR100398470B1 (ko) | 2002-10-30 | 2003-09-19 | 충청북도 | 연하식품 및 그 제조 방법 |
US7455869B2 (en) | 2002-12-19 | 2008-11-25 | San-Ei Gen F.F.I., Inc. | Composition for preparing artificial fruit flesh and food product containing the same |
NL1022254C2 (nl) | 2002-12-23 | 2004-06-24 | Thomas Uljee Beheer B V | Natuurlijk bloemmengsel, alsmede daaruit verkregen bakkerij producten. |
CA2694872A1 (en) | 2003-01-31 | 2004-08-19 | Simply Thick Llc | Improved thickened beverages for dysphagia |
US20050175759A1 (en) * | 2004-02-09 | 2005-08-11 | Atul Singhal | Newborn infant formulas and feeding methods |
US8394370B2 (en) * | 2003-06-23 | 2013-03-12 | Nestec S.A. | Nutritional formula for optimal gut barrier function |
DK1841332T4 (da) | 2004-11-18 | 2013-05-06 | Nutricia Nv | Fortykningsmiddelsammensætning til dysfagipatienter |
FR2913857A1 (fr) * | 2007-03-22 | 2008-09-26 | United Pharmaceuticals Soc Par | Procede de preparation d'un lait infantile anti-regurgitation |
WO2009012889A1 (en) * | 2007-07-24 | 2009-01-29 | Cargill, Incorporated | Fermented dairy products |
EP2418969B1 (en) | 2009-04-15 | 2013-03-06 | N.V. Nutricia | Anti-reflux infant nutrition |
-
2010
- 2010-04-15 EP EP10713037A patent/EP2418969B1/en active Active
- 2010-04-15 PT PT107130379T patent/PT2418969E/pt unknown
- 2010-04-15 US US13/264,704 patent/US10602752B2/en active Active
- 2010-04-15 ES ES10713037T patent/ES2410376T3/es active Active
- 2010-04-15 PL PL10713037T patent/PL2418969T3/pl unknown
- 2010-04-15 CN CN2010800254012A patent/CN102802439A/zh active Pending
- 2010-04-15 CN CN201610178267.9A patent/CN105852118A/zh active Pending
- 2010-04-15 WO PCT/NL2010/050192 patent/WO2010120172A1/en active Application Filing
- 2010-04-15 RU RU2011146162/13A patent/RU2524201C2/ru active
-
2020
- 2020-03-18 US US16/823,076 patent/US11490631B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1159207A (zh) * | 1994-08-31 | 1997-09-10 | 热尔韦·达诺尼公司 | 用嗜热链球菌制备富含半乳糖-低聚糖和β-半乳糖苷酶的发酵产品 |
CN101228262A (zh) * | 2005-07-21 | 2008-07-23 | 株式会社益力多本社 | 新型双歧杆菌属细菌及其利用 |
JP2008237186A (ja) * | 2007-03-29 | 2008-10-09 | Nof Corp | ゲル状流動食 |
Non-Patent Citations (2)
Title |
---|
REIKO MIYAZAWA等: "Effect of Locust Bean Gum in Anti-regurgitant Milk on the Regurgitation in Uncomplicated Gastroesophageal Reflux", <JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION> * |
黄来发: "《食品增稠剂-2版》", 31 January 2009, 中国轻工业出版社 * |
Also Published As
Publication number | Publication date |
---|---|
PL2418969T3 (pl) | 2013-08-30 |
US11490631B2 (en) | 2022-11-08 |
EP2418969B1 (en) | 2013-03-06 |
RU2011146162A (ru) | 2013-05-20 |
EP2418969A1 (en) | 2012-02-22 |
ES2410376T3 (es) | 2013-07-01 |
US20120213858A1 (en) | 2012-08-23 |
PT2418969E (pt) | 2013-06-05 |
US10602752B2 (en) | 2020-03-31 |
RU2524201C2 (ru) | 2014-07-27 |
WO2010120172A1 (en) | 2010-10-21 |
CN102802439A (zh) | 2012-11-28 |
US20200214309A1 (en) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11490631B2 (en) | Anti-reflux infant nutrition | |
RU2762984C2 (ru) | Способ стимуляции кишечной флоры | |
EP2285387B1 (en) | Nutrition for prevention of infections | |
CA2753083C (en) | Symbiotic maple product compositions and methods | |
US20110150851A1 (en) | Nutritional composition for infants delivered via caesarean section | |
WO2009151315A1 (en) | Nutritional composition for infants delivered via caesarean section | |
TW201002216A (en) | Probiotics to improve gut microbiota | |
WO2017114900A1 (en) | Fermented formula with non-digestible oligosaccharides | |
EP3397075A1 (en) | Nutritional formula with non-digestible oligosaccharides and non-replicating lactic acid producing bacteria | |
US20160206658A1 (en) | Nutrition for prevention of infections | |
CN109688839A (zh) | 发酵的婴儿配方物 | |
WO2019155044A1 (en) | Fermented formula with non-digestible oligosaccharides | |
Chittiprolu | Effect of starch spherulites on survival of bifidobacteria in the presence of acid or bile | |
CA2657291A1 (en) | Symbiotic maple product compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160817 |
|
RJ01 | Rejection of invention patent application after publication |